|
Frailty in GLP-1s, PRS for CVD, and European Guidelines By Viktor Zarev, Virginia Hunt
September 17, 2026
|
|
|
|
|
Together with
|
|
|
|
“This is wrong on so many levels and unnecessarily pessimistic. Atherosclerosis is strongly age-associated, but calling it part of the normal aging process implies that it is inevitable and that there is nothing we can do about it… Detaching the clinical endpoints (e.g., myocardial infarction and some ischemic strokes) from atherosclerotic plaques is to ignore tons of biomedical literature going back > 150 years.”
|
|
Marios Georgakis, MD, PhD, responding to John Mandrola, MD’s views on atherosclerosis and aging which spurred a massive debate on X.
|
|
|
Whether you watched it live or haven’t seen it yet, Cardiac Wire’s webinar with Dr. Matthew Budoff and Dr. Jonathon Leipsic is an invaluable source of information on how cardiac CT is shaping the way we detect and treat structural heart disease. Watch it here on YouTube.
On the topic of shaping treatment, today’s top story is a good example of how data can do just that.
Thanks for reading,
Vik
|
|
|
|
A new secondary analysis of the SELECT trial pushes back on the instinct for avoiding new semaglutide prescriptions in frail patients after finding that the drug delivered its CV benefits regardless of frailty.
- Clinicians often hesitate to start frail patients on new medications, worried the risks outweigh the benefits due to potential for intolerance or adverse safety outcomes.
- That hesitation is also true for Novo’s Wegovy (semaglutide) since it can aggressively reduce body mass, and in some cases muscle mass.
With how new GLP-1s still are, it’s worth testing if they fit the frailty mold. Thus, researchers analyzed 17.6k patients from SELECT with CVD and overweight/obesity, but without diabetes and sorted them into three frailty categories finding that…
- Semaglutide’s effect on CV death, nonfatal MI, and nonfatal stroke was consistent across all three frailty categories.
- That also held true for HF outcomes, with all-cause hospitalization, and all-cause mortality showing no meaningful difference due to frailty.
- Notably, the frailest patients had the highest baseline negative event rates, meaning they had the most risk to reduce.
However, the quality-of-life and safety findings are where frailty matters most, and in this case, Semaglutide shined.
- Improvement in health-related QoL was greater in patients with higher frailty.
- The frailest patients taking semaglutide were more likely to see their frailty improve (OR: 2.46) and less likely to see it worsen (OR: 0.47) over 104 weeks.
- Counterintuitively, adverse events leading to treatment discontinuation were lower in frailer patients on semaglutide than placebo.
The clinical trend in these data makes it seem like there isn’t a good reason to withhold GLP-1 therapy from frail patients.
- If anything, this subanalysis argues that frailer patients may stand to gain the most from semaglutide, both in outcomes and in day-to-day functioning.
- That said, this analysis doesn’t show why this happens, just that it does.
The Takeaway
Sometimes a new drug challenges the old way of doing things, and when it comes to CVD and frailty, Semaglutide is doing just that. Clinicians can rest a little easier now when considering GLP-1s for their frailest patients.
|
|
Smarter STEMI Care With Viz.ai
Reducing false activations and unnecessary transfers helps save critical time and resources for both patients and health systems. Hear from Gregory Means, MD, about his experience using Viz.ai to access EKGs and surface patient history in one place.
|
|
Corbotics and Us2.ai’s End-to-End Automated Echo
There’s a growing demand for cardiac imaging in the face of sonographer shortages and increasing pressure on specialist resources. That’s why Us2.ai and Corbotics are combining autonomous robotic echo acquisition with AI-powered analysis to create an end-to-end automated echocardiography workflow.
|
|
A Cardiovascular Ultrasound Platform You Can Trust
Being able to provide premium diagnostic information for your pediatric patients every day, all day, is vital. Find out why cardiac imagers trust Fujifilm’s Lisendo 880, and how its premium imaging quality, efficiency tools, and reliability you can trust, have helped change workflows for clinicians and technologists alike.
|
|
- PRS for Hidden CVD: It’s rare that one gene causes CVD, just as it’s rare for one CV condition to occur in isolation. As part of a recent JACC issue, researchers used data from 245k patients to develop a new eight-condition polygenic risk score (PRS) that successfully predicted which patients had the highest risk of developing CVD based on their genes. Going one step further, researchers incorporated the PRS into the AHA’s PREVENT risk assessment leading to an 18% improvement in CAD-risk classification. You can read Cardiac Wire’s full coverage here.
- FDA Approves TAVR Embolic Protection: Emboline received FDA 510(k) clearance for its Emboliner Embolic Protection System that captures and removes embolic debris during TAVR before it can reach the brain and other organs. The Emboliner uses a circumferential dual-layer filter to achieve cerebral and systemic protection, which distinguishes it from the current cerebral blood vessel devices on the market. Its clearance stems from the PROTECT H2H study, which showed significantly greater debris capture than Boston Scientific’s Sentinel system. Emboline plans a phased U.S. launch later this year.
- PREVENT Equations Arrive in Epic: America’s most widely used EHR, Epic, now comes with the AHA’s PREVENT risk equations built-in. Originally introduced in 2023 to replace the older Pooled Cohort Equations, the PREVENT tools help estimate 10- and 30-year risks of MI, stroke, and HF in adults 30-79 without prior CVD. Automating the equations within the Epic EHR ecosystem is intended to reduce friction in busy practices, which the AHA believes will free clinicians to focus on patient conversations and shared decision-making.
- A New Cardiac Wearable: Entering the next generation of its ambulatory ECG wearable offerings, Peerbridge Health received FDA 510(k) clearance for Peerbridge Cor MDx. The device records continuous multi-channel ECG for up to 14 days using Eindhoven’s triangle and is designed to preserve waveform morphology and P-wave definition. Cor MDx will also serve as the foundation for Peerbridge’s broader cardiac intelligence platform that is intended to use AI for monitoring ejection fraction severity and obstructive sleep apnea, though those remain investigational.
- Night Light Linked to HF: Just the light bleeding in underneath a bedroom door at night may be enough to harm the heart’s long-term structure and function. Among 11.1k participants, those with high nighttime light exposure showed impaired myocardial deformation and adverse ventricular changes compared to those with no exposure three years after initial tests. The high-risk cohort also had an increased risk of HF and stroke (+29% and +33%, respectively). These effects appeared to be linked to the toll of light on sleep duration.
- AliveCor Debuts KardiaACCESS: AliveCor took the lid off KardiaACCESS to serve as the bridge between care teams and patients managing their blood pressure, diabetes, and heart health – both in and out of the office. As the name would suggest, the new CMS ACCESS model allows KardiaACCESS to support eligible Medicare beneficiaries with clinician-guided care and connected health tools at $0 out-of-pocket cost. Rather than treating symptoms in isolation, KardiaACCESS treats the Cardio-Kidney-Metabolic system as a whole, addressing the links between BP, lipids, and kidney function to keep patients out of the hospital.
- Stock AI in Drug Design: A Chinese biotech used off-the-shelf AI to create a genuinely promising blood pressure drug. Sheo Pharmaceuticals detailed its process during the American Chemical Society’s fall conference. With help from ChatGPT and Gemini, the company synthesized 200 renin inhibitors before landing on a lead. The resulting drug went on to beat aliskiren, the only renin inhibitor to ever reach markets, at controlling hypertension in monkeys.
- Ramipril Recalled: More than 28k bottles of the anti-hypertensive drug ramipril have been recalled after high levels of a chemical byproduct led to a failed purity test. While the FDA noted elevated levels of the dicyclohexylurea byproduct are unlikely to cause serious harm, they did warn that patients who take the medication could face temporary health issues. The two lots included in the recall carry 10-mg pills with 2027 expiration dates that were distributed across Florida by Exelan Pharmaceuticals.
- New ESC HF Guidelines: The ESC’s updated HF guidelines incorporate major changes, including staging criteria borrowed from 2022 U.S. guidelines and a goodbye to the HFmrEF classification. Because of overlapping treatment recommendations and outcomes, patients previously included in the HFmrEF category (LVEF 41%-49%) now meet expanded qualifications for HFrEF (LVEF <50%). New labels may also help clinicians sort through the growing list of HF treatments, with interventions now tagged as foundational medical therapy, additional medical therapy, or guideline-directed interventional therapy.
- More ESC Guidelines for CKD + CVD: But wait! There’s more… guidelines! The ESC also partnered with the European Renal Association, to release its first ever guidelines for managing patients with both CVD and CKD. The new guidelines introduce the “STAMP” framework (Screen, Triage, Address CKD risk, Modify CVD management, Plan) and urge cardiologists to test urine albumin, not just eGFR, while prioritizing proven therapies like SGLT2is, finerenone, and GLP-1 agonists in high-risk patients. The guidelines closely mirror the AHA/ACC/ADA’s cardio-kidney-metabolic guidelines released in June.
- SGK1is Soothe HF: People born with genetic variants decreasing SGK1 expression have lower HF risk. Now, Thryv Therapeutics is trying to bring that benefit to a broader group with their SGK1 inhibitor, THRV-1268. Results from two Phase 1 studies showed obese patients randomized to THRV-1268 had better electrical stability and no serious adverse events, but the big news came with dual SGLT2i/SGK1i therapy. Preclinical animal models showed the duo worked better than each therapy alone, achieving near-normal LVEF alongside remodeling of the cardiac tissue itself.
|
|
9 Merge Cardio Features to Change Your Cardiology Workflows
Having the right tools is essential for efficient cardiology imaging workflows and delivering exceptional patient care. Read this article on how Merge Cardio can make the biggest difference to your imaging workflows, care team user experiences, and patient care delivery.
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
The Benefits of Cardiovascular Structured Reporting
Cardiovascular imaging’s growing demand means providers need structured reporting to manage their clinical workflows. Discover why Optum’s structured reports allow for more automated EHR and modality data while helping standardize clinical workflows.
|
|
- State-of-the-Art Cardiac Monitoring at Scale: Cleared for 13 different heart rhythm interpretations, AccurKardia’s AccurECG 2.0 shortens the time from an arrhythmia incident to clinical intervention. Watch here to find out how AccurKardia and Specialized Medical are teaming up to bring the AccurECG 2.0 technology to clinicians across the U.S.
- VASCADE MVP® XL Vascular Closure System: Sometimes EP procedures call for a venous vascular closure system that is simply bigger. Haemonetics’ VASCADE MVP XL closure system comes with 58% more collagen and a 9% larger disc compared to the VASCADE MVP system as well as an expanded indication for utilizing 10-14F inner diameter sheaths.
- Telemedicine Isn’t About Technology. It’s About People. With temporary telehealth rules expiring, millions of Medicare patients may lose their ability to see their doctors remotely. Read why Monebo and the Alliance for Connected Care are urging Congress to make telemedicine a permanent part of the healthcare system.
- How AI Expands the Role of CMR Experts: If you’re an MRI technologist, AI could be the best thing that ever happened to your career. Read here to learn about the benefits of AI for CMR experts and how it can accelerate both your training and career.
- Canon’s 30 Years of Caring: For over 30 years, Canon has helped advance pediatric interventional cardiology through innovation and a commitment to better care. Learn more about how and why modern pediatric cardiac angiography came to be from one of its founding members, Dr. John P. Cheatham.
- Circle CVI’s cvi42 v6.5 is Now Live! Cardiovascular imaging plays a critical role in helping care teams with everything from prevention to procedural planning. That’s why Circle Cardiovascular Imaging released v6.5 of its cvi42 software with features like automated phase offset correction, editable plaque segmentation, and quantitative perfusion to support every aspect of CV imaging workflows.
- What Every Cardiologist Needs to Watch for in Heart Failure: Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.
|
|
|
|
|